Aging Brain's Hidden Gatekeepers: TREM2/TIM3 Immune Cells Drive Neurodegeneration

Aging is increasingly understood not just as cellular wear-and-tear but as a systemic shift in immune and vascular regulation that sets the stage for diverse brain pathologies. This study tackles a fundamental question: do gliomas and Alzheimer's disease share a common aging-driven mechanism rooted in vascular and immune dysfunction?

Using bulk RNAseq, single-cell RNAseq (scRNAseq), bioinformatics, immunohistochemistry, and validated patient cohorts (42 glioma patients, 32 Alzheimer's/healthy brain samples), the researchers systematically characterized blood-brain barrier (BBB) integrity, neuronal synapse gene expression, and immune cell composition across aging and disease states. Public datasets including TCGA glioma/GBM cohorts and the Hisayama and Berchtold brain aging studies provided extensive validation. A mouse glioblastoma model incorporating the IDH mutation was used to experimentally test vascular normalization strategies.

A striking age threshold emerged: significant BBB dysfunction and a corresponding decline in neuronal synapse integrity both crossed meaningful thresholds at approximately 57 years of age. This was not merely correlative — patients with high BBB dysfunction scores had dramatically shorter survival (1525 days) compared to those with low BBB dysfunction (4084 days), underscoring the clinical weight of this finding. BBB breakdown was directly correlated with brain aging and disease progression in both glioma and Alzheimer's disease contexts.

The immune analysis revealed a hallmark of immunoaging: an imbalance between pro- and anti-inflammatory signals that promotes the extravasation of monocyte-derived macrophages into the brain parenchyma — an 85% increase in these infiltrating cells was documented. Critically, the infiltrating macrophages bore a suppressive phenotype marked by co-expression of TREM2 and TIM3, receptors associated with immune checkpoint regulation and myeloid dysfunction. These cells appear to suppress anti-tumor and anti-neurodegenerative immune responses while simultaneously maintaining a pro-inflammatory cytokine milieu, creating a toxic neuroinflammatory environment. ScRNAseq data from GBM and Alzheimer's datasets confirmed the presence and transcriptional identity of these TREM2+/TIM3+ myeloid populations in human disease tissue.

In the mouse glioblastoma model, vascular normalization — achieved in part through incorporation of the IDH mutation — reversed neuronal loss and reduced tumor aggressiveness, providing causal evidence that BBB dysfunction drives pathology rather than merely accompanying it. Furthermore, reactivating the aging immune system in this model could prevent tumor development, pointing toward immunotherapeutic strategies. Together, these findings position BBB dysfunction as a convergent, age-associated process that licenses suppressive myeloid cells to govern chronic neuroinflammation across fundamentally different CNS diseases.